论文部分内容阅读
当病人住院后拟诊为心肌梗塞,即可口服或静脉给β-阻滞剂治疗.病人出院时,β-阻滞剂可在开始的“高危险”阶段用药,或长期口服。这方面现在至少有41组随机试验,总数达2万人.故而,现在可以值得对它们进行评价. 目前最有条件进行评价的是在心肌便塞后Ⅰ周开始的较长时间用β-阻滞剂治疗的效果。至少有11组β-阻滞剂在心肌梗塞后开始口服,继续服用
When the patient is hospitalized to be diagnosed with MI, oral or intravenous β-blocker therapy is given and the patient is discharged at the “high-risk” stage of the initial dose or long-term oral. There are now at least 41 randomized trials in this area for a total of 20,000 people, and they are now worth evaluating, and the most current assessment is that β-blockade Delayed agent treatment effect. At least 11 groups of β-blockers are taken orally after myocardial infarction and continue to be taken